How Big Will the SpaceX IPO Be?
Operated up to now as a private business, SpaceX will…
Buy
52
HAE Quote, Financials, Valuation and Earnings
Last price:
$66.66
Seasonality move
:
-1.38%
Day range:
$64.99 - $66.68
52-week range:
$47.32 - $87.32
Dividend yield:
0%
P/E ratio:
19.45x
P/S ratio:
2.46x
P/B ratio:
3.67x
Volume:
1M
Avg. volume:
721.7K
1-year change:
-4.04%
Market cap:
$3.1B
Revenue:
$1.4B
EPS (TTM):
$3.43
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
HAE
Haemonetics Corp.
|
$334M | $1.19 | 2.17% | 10.67% | $92.00 |
|
ABT
Abbott Laboratories
|
$11.9B | $1.39 | 6.11% | 55.12% | $134.24 |
|
DXCM
DexCom, Inc.
|
$1.3B | $0.60 | 13.59% | 79.17% | $85.19 |
|
MASI
Masimo Corp.
|
$398.2M | $1.39 | 7.08% | 565.51% | $183.75 |
|
SOLV
Solventum Corp.
|
$2B | $1.62 | -5.67% | 87.42% | $89.25 |
|
TNDM
Tandem Diabetes Care, Inc.
|
$267.1M | -$0.30 | 6.15% | -78.57% | $25.95 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
HAE
Haemonetics Corp.
|
$66.66 | $92.00 | $3.1B | 19.45x | $0.00 | 0% | 2.46x |
|
ABT
Abbott Laboratories
|
$109.30 | $134.24 | $190.1B | 29.51x | $0.63 | 2.2% | 4.31x |
|
DXCM
DexCom, Inc.
|
$73.04 | $85.19 | $28.5B | 40.65x | $0.00 | 0% | 6.59x |
|
MASI
Masimo Corp.
|
$137.33 | $183.75 | $7.4B | 116.80x | $0.00 | 0% | 4.34x |
|
SOLV
Solventum Corp.
|
$76.97 | $89.25 | $13.4B | 8.86x | $0.00 | 0% | 1.60x |
|
TNDM
Tandem Diabetes Care, Inc.
|
$19.89 | $25.95 | $1.3B | -- | $0.00 | 0% | 1.32x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
HAE
Haemonetics Corp.
|
59.05% | -0.136 | 53.75% | 0.93x |
|
ABT
Abbott Laboratories
|
20.25% | 0.321 | -- | 1.12x |
|
DXCM
DexCom, Inc.
|
48.58% | 1.837 | 9.81% | 1.33x |
|
MASI
Masimo Corp.
|
41.99% | 0.887 | 7.4% | 1.68x |
|
SOLV
Solventum Corp.
|
50.75% | 0.850 | 40.57% | 0.94x |
|
TNDM
Tandem Diabetes Care, Inc.
|
77.16% | 1.942 | 54.61% | 1.79x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
HAE
Haemonetics Corp.
|
$183.4M | $67.3M | 7.99% | 19.39% | 20.56% | $106.3M |
|
ABT
Abbott Laboratories
|
$6.5B | $2.4B | 10.2% | 29.06% | 20.59% | $2.3B |
|
DXCM
DexCom, Inc.
|
$747.4M | $242.5M | 14.67% | 30.94% | 20.05% | $579.4M |
|
MASI
Masimo Corp.
|
$230.6M | $83.7M | -11.41% | -19.18% | 22.53% | $49.7M |
|
SOLV
Solventum Corp.
|
$1.1B | $171M | 13.6% | 42.2% | 8.16% | -$21M |
|
TNDM
Tandem Diabetes Care, Inc.
|
$134.3M | -$20.1M | -31.16% | -110.24% | -8.05% | $4.2M |
Haemonetics Corp. vs. Competitors
-
Which has Higher Returns HAE or ABT?
Abbott Laboratories has a net margin of 11.82% compared to Haemonetics Corp.'s net margin of 15.5%. Haemonetics Corp.'s return on equity of 19.39% beat Abbott Laboratories's return on equity of 29.06%.
Company Gross Margin Earnings Per Share Invested Capital HAEHaemonetics Corp.56.04% $0.81 $2.1B ABTAbbott Laboratories57.09% $1.02 $64.2B -
What do Analysts Say About HAE or ABT?
Haemonetics Corp. has a consensus price target of $92.00, signalling upside risk potential of 38.01%. On the other hand Abbott Laboratories has an analysts' consensus of $134.24 which suggests that it could grow by 23.2%. Given that Haemonetics Corp. has higher upside potential than Abbott Laboratories, analysts believe Haemonetics Corp. is more attractive than Abbott Laboratories.
Company Buy Ratings Hold Ratings Sell Ratings HAEHaemonetics Corp.3 4 0 ABTAbbott Laboratories15 7 0 -
Is HAE or ABT More Risky?
Haemonetics Corp. has a beta of 0.293, which suggesting that the stock is 70.687% less volatile than S&P 500. In comparison Abbott Laboratories has a beta of 0.721, suggesting its less volatile than the S&P 500 by 27.854%.
-
Which is a Better Dividend Stock HAE or ABT?
Haemonetics Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Abbott Laboratories offers a yield of 2.2% to investors and pays a quarterly dividend of $0.63 per share. Haemonetics Corp. pays -- of its earnings as a dividend. Abbott Laboratories pays out 64.34% of its earnings as a dividend. Abbott Laboratories's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios HAE or ABT?
Haemonetics Corp. quarterly revenues are $327.3M, which are smaller than Abbott Laboratories quarterly revenues of $11.5B. Haemonetics Corp.'s net income of $38.7M is lower than Abbott Laboratories's net income of $1.8B. Notably, Haemonetics Corp.'s price-to-earnings ratio is 19.45x while Abbott Laboratories's PE ratio is 29.51x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Haemonetics Corp. is 2.46x versus 4.31x for Abbott Laboratories. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HAEHaemonetics Corp.2.46x 19.45x $327.3M $38.7M ABTAbbott Laboratories4.31x 29.51x $11.5B $1.8B
-
Which has Higher Returns HAE or DXCM?
DexCom, Inc. has a net margin of 11.82% compared to Haemonetics Corp.'s net margin of 23.47%. Haemonetics Corp.'s return on equity of 19.39% beat DexCom, Inc.'s return on equity of 30.94%.
Company Gross Margin Earnings Per Share Invested Capital HAEHaemonetics Corp.56.04% $0.81 $2.1B DXCMDexCom, Inc.61.8% $0.70 $5.3B -
What do Analysts Say About HAE or DXCM?
Haemonetics Corp. has a consensus price target of $92.00, signalling upside risk potential of 38.01%. On the other hand DexCom, Inc. has an analysts' consensus of $85.19 which suggests that it could grow by 16.64%. Given that Haemonetics Corp. has higher upside potential than DexCom, Inc., analysts believe Haemonetics Corp. is more attractive than DexCom, Inc..
Company Buy Ratings Hold Ratings Sell Ratings HAEHaemonetics Corp.3 4 0 DXCMDexCom, Inc.20 3 0 -
Is HAE or DXCM More Risky?
Haemonetics Corp. has a beta of 0.293, which suggesting that the stock is 70.687% less volatile than S&P 500. In comparison DexCom, Inc. has a beta of 1.480, suggesting its more volatile than the S&P 500 by 48.047%.
-
Which is a Better Dividend Stock HAE or DXCM?
Haemonetics Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. DexCom, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Haemonetics Corp. pays -- of its earnings as a dividend. DexCom, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios HAE or DXCM?
Haemonetics Corp. quarterly revenues are $327.3M, which are smaller than DexCom, Inc. quarterly revenues of $1.2B. Haemonetics Corp.'s net income of $38.7M is lower than DexCom, Inc.'s net income of $283.8M. Notably, Haemonetics Corp.'s price-to-earnings ratio is 19.45x while DexCom, Inc.'s PE ratio is 40.65x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Haemonetics Corp. is 2.46x versus 6.59x for DexCom, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HAEHaemonetics Corp.2.46x 19.45x $327.3M $38.7M DXCMDexCom, Inc.6.59x 40.65x $1.2B $283.8M
-
Which has Higher Returns HAE or MASI?
Masimo Corp. has a net margin of 11.82% compared to Haemonetics Corp.'s net margin of 14.46%. Haemonetics Corp.'s return on equity of 19.39% beat Masimo Corp.'s return on equity of -19.18%.
Company Gross Margin Earnings Per Share Invested Capital HAEHaemonetics Corp.56.04% $0.81 $2.1B MASIMasimo Corp.62.07% -$1.86 $1.4B -
What do Analysts Say About HAE or MASI?
Haemonetics Corp. has a consensus price target of $92.00, signalling upside risk potential of 38.01%. On the other hand Masimo Corp. has an analysts' consensus of $183.75 which suggests that it could grow by 33.8%. Given that Haemonetics Corp. has higher upside potential than Masimo Corp., analysts believe Haemonetics Corp. is more attractive than Masimo Corp..
Company Buy Ratings Hold Ratings Sell Ratings HAEHaemonetics Corp.3 4 0 MASIMasimo Corp.4 3 0 -
Is HAE or MASI More Risky?
Haemonetics Corp. has a beta of 0.293, which suggesting that the stock is 70.687% less volatile than S&P 500. In comparison Masimo Corp. has a beta of 1.263, suggesting its more volatile than the S&P 500 by 26.337%.
-
Which is a Better Dividend Stock HAE or MASI?
Haemonetics Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Masimo Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Haemonetics Corp. pays -- of its earnings as a dividend. Masimo Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios HAE or MASI?
Haemonetics Corp. quarterly revenues are $327.3M, which are smaller than Masimo Corp. quarterly revenues of $371.5M. Haemonetics Corp.'s net income of $38.7M is lower than Masimo Corp.'s net income of $53.7M. Notably, Haemonetics Corp.'s price-to-earnings ratio is 19.45x while Masimo Corp.'s PE ratio is 116.80x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Haemonetics Corp. is 2.46x versus 4.34x for Masimo Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HAEHaemonetics Corp.2.46x 19.45x $327.3M $38.7M MASIMasimo Corp.4.34x 116.80x $371.5M $53.7M
-
Which has Higher Returns HAE or SOLV?
Solventum Corp. has a net margin of 11.82% compared to Haemonetics Corp.'s net margin of 60.4%. Haemonetics Corp.'s return on equity of 19.39% beat Solventum Corp.'s return on equity of 42.2%.
Company Gross Margin Earnings Per Share Invested Capital HAEHaemonetics Corp.56.04% $0.81 $2.1B SOLVSolventum Corp.53.91% $7.22 $10.1B -
What do Analysts Say About HAE or SOLV?
Haemonetics Corp. has a consensus price target of $92.00, signalling upside risk potential of 38.01%. On the other hand Solventum Corp. has an analysts' consensus of $89.25 which suggests that it could grow by 15.95%. Given that Haemonetics Corp. has higher upside potential than Solventum Corp., analysts believe Haemonetics Corp. is more attractive than Solventum Corp..
Company Buy Ratings Hold Ratings Sell Ratings HAEHaemonetics Corp.3 4 0 SOLVSolventum Corp.5 5 1 -
Is HAE or SOLV More Risky?
Haemonetics Corp. has a beta of 0.293, which suggesting that the stock is 70.687% less volatile than S&P 500. In comparison Solventum Corp. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock HAE or SOLV?
Haemonetics Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Solventum Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Haemonetics Corp. pays -- of its earnings as a dividend. Solventum Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios HAE or SOLV?
Haemonetics Corp. quarterly revenues are $327.3M, which are smaller than Solventum Corp. quarterly revenues of $2.1B. Haemonetics Corp.'s net income of $38.7M is lower than Solventum Corp.'s net income of $1.3B. Notably, Haemonetics Corp.'s price-to-earnings ratio is 19.45x while Solventum Corp.'s PE ratio is 8.86x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Haemonetics Corp. is 2.46x versus 1.60x for Solventum Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HAEHaemonetics Corp.2.46x 19.45x $327.3M $38.7M SOLVSolventum Corp.1.60x 8.86x $2.1B $1.3B
-
Which has Higher Returns HAE or TNDM?
Tandem Diabetes Care, Inc. has a net margin of 11.82% compared to Haemonetics Corp.'s net margin of -8.49%. Haemonetics Corp.'s return on equity of 19.39% beat Tandem Diabetes Care, Inc.'s return on equity of -110.24%.
Company Gross Margin Earnings Per Share Invested Capital HAEHaemonetics Corp.56.04% $0.81 $2.1B TNDMTandem Diabetes Care, Inc.53.88% -$0.31 $582.2M -
What do Analysts Say About HAE or TNDM?
Haemonetics Corp. has a consensus price target of $92.00, signalling upside risk potential of 38.01%. On the other hand Tandem Diabetes Care, Inc. has an analysts' consensus of $25.95 which suggests that it could grow by 30.48%. Given that Haemonetics Corp. has higher upside potential than Tandem Diabetes Care, Inc., analysts believe Haemonetics Corp. is more attractive than Tandem Diabetes Care, Inc..
Company Buy Ratings Hold Ratings Sell Ratings HAEHaemonetics Corp.3 4 0 TNDMTandem Diabetes Care, Inc.7 13 0 -
Is HAE or TNDM More Risky?
Haemonetics Corp. has a beta of 0.293, which suggesting that the stock is 70.687% less volatile than S&P 500. In comparison Tandem Diabetes Care, Inc. has a beta of 1.682, suggesting its more volatile than the S&P 500 by 68.218%.
-
Which is a Better Dividend Stock HAE or TNDM?
Haemonetics Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Tandem Diabetes Care, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Haemonetics Corp. pays -- of its earnings as a dividend. Tandem Diabetes Care, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios HAE or TNDM?
Haemonetics Corp. quarterly revenues are $327.3M, which are larger than Tandem Diabetes Care, Inc. quarterly revenues of $249.3M. Haemonetics Corp.'s net income of $38.7M is higher than Tandem Diabetes Care, Inc.'s net income of -$21.2M. Notably, Haemonetics Corp.'s price-to-earnings ratio is 19.45x while Tandem Diabetes Care, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Haemonetics Corp. is 2.46x versus 1.32x for Tandem Diabetes Care, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HAEHaemonetics Corp.2.46x 19.45x $327.3M $38.7M TNDMTandem Diabetes Care, Inc.1.32x -- $249.3M -$21.2M
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Where Will ISRG Stock Be in 5 Years?
Intuitive Surgical (NASDAQ:ISRG) is the innovative medical tech business behind…
Is Kratos Stock a Good Investment?
UAV and hypersonic system defense contractor Kratos (NASDAQ:KTOS) has swung…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 65x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 42x
Sell
50
Is GOOGL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 42x
Alerts
Sell
40
GDXU alert for Jan 31
MicroSectors Gold Miners 3X Leveraged ETN [GDXU] is down 38.85% over the past day.
Sell
34
PFSI alert for Jan 31
PennyMac Financial Services, Inc. [PFSI] is down 33.21% over the past day.
Sell
40
SHNY alert for Jan 31
MicroSectors Gold 3X Leveraged ETN [SHNY] is down 31.56% over the past day.
